Hyderabad: Prime Minister Narendra Modi reviewed the COVID-19 vaccine development and manufacturing process at Hyderabad's Bharat Biotech facility as part of his three-city visit.
Mr. Modi congratulated the scientists of Bharat Biotech and tweeted, "At the Bharat Biotech facility in Hyderabad, was briefed about their indigenous COVID-19 vaccine. Congratulated the scientists for their progress in the trials so far. Their team is closely working with ICMR to facilitate speedy progress."
Earlier in the morning, the Prime Minister visited Zydus Biotech Park at Ahmedabad. Next, he will next the Serum Institute of India (SII) in Pune.
On 16 November, Bharat Biotech had announced the commencement of phase III trials of Covaxin and said the trials will involve 26,000 volunteers across 25 centres in India. This is India's first phase III efficacy study for a COVID-19 vaccine and the largest one ever conducted in India.
Covaxin, India's indigenous COVID-19 vaccine, is being developed in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). The indigenous inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility. Covaxin is a highly purified and inactivated vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied.